In:
Molecular Oncology, Wiley, Vol. 12, No. 8 ( 2018-08), p. 1296-1307
Abstract:
Recent advances in mass spectrometry ( MS )‐based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine‐specific histone demethylase 1 ( LSD 1/ KDM 1A). LSD 1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.
Type of Medium:
Online Resource
ISSN:
1574-7891
,
1878-0261
DOI:
10.1002/mol2.2018.12.issue-8
DOI:
10.1002/1878-0261.12326
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2322586-5